Freestone Grove Partners LP Travere Therapeutics, Inc. Transaction History
Freestone Grove Partners LP
- $9.71 Trillion
- Q1 2025
Shares
1 transactions
Others Institutions Holding TVTX
# of Institutions
239Shares Held
99.9MCall Options Held
1.79MPut Options Held
555K-
Armistice Capital, LLC New York, NY8.87MShares$141 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$121 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$119 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$79.4 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$76 Million0.11% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.02B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...